Provides software that analyzes heart scans to help physicians diagnose and manage coronary artery disease.
10-K for FY2025, filed Mar 18, 2026We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution…View ↗
Heartflow enhances CCTA, the most advanced non-invasive imaging modality for assessing CAD, with AI-powered analysis to deliver more…View ↗
Our Heartflow Platform seamlessly integrates into our customer workflows, providing clinically actionable insights directly to the account…View ↗
Medical providers pay each time a physician orders a requested analysis. Heartflow generally bills when it delivers the analysis to the physician; subscriptions for unlimited analyses are paid upfront and charged over the contract term.
10-K for FY2025, filed Mar 18, 2026
$176M
10-K for FY2025, filed Mar 18, 2026
$176M ↗
Medical providers, including hospitals and outpatient imaging facilities, use the platform through their clinical workflows. Heartflow sells through a direct sales organization in the United States and has small direct commercial teams in the United Kingdom, Japan and other European Union countries.
10-K for FY2025, filed Mar 18, 2026When a patient presents with symptoms of CAD and their physician follows the AHA and ACC Class 1, Level A chest pain guidelines by…View ↗
Our Heartflow Platform seamlessly integrates into our customer workflows, providing clinically actionable insights directly to the account…View ↗
We market and sell our Heartflow Platform in the United States through a direct sales organization. We have developed a highly scalable…View ↗
We also have small, direct commercial teams in the United Kingdom, Japan and other countries in the European Union. We may continue to…View ↗
No. It lost $116.8M in FY2025.
10-K for FY2025, filed Mar 18, 2026
−$64.1MView ↗
10-K for FY2025, filed Mar 18, 2026
−$116.8MView ↗
10-K for FY2025, filed Mar 18, 2026
−$59MView ↗
10-Q for Q2 FY2026, filed Aug 13, 2026
−$15.7MView ↗
8-K, filed Aug 13, 2026
Total revenue of $246 million to $250 million (approximately 40% to 42% growth year-over-year), compared to previous guidance of $228…View ↗
Growing.
Revenue grew 2.0x in 2 years, from $87.2M in FY2023 to $176M in FY2025, about 42% a year.
10-K for FY2025, filed Mar 18, 2026
Competes with Siemens Healthineers, GE Healthcare, Koninklijke Philips, Canon Medical Systems, Cleerly, Elucid Bioimaging, and Keya Medical Technology
10-K for FY2025, filed Mar 18, 2026We consider our primary competition to be traditional non-invasive tests for CAD including primarily stress tests such as SPECT, stress…View ↗
Loading...